ChiYoungOkMD

Hematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Physician

Dr. Ok is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 2012 - 2013
UMass Chan Medical SchoolResidency, Pathology-Anatomic and Clinical, 2008 - 2012
Yonsei University College of MedicineClass of 2004

PubMed

Advancing Diagnostic Accuracy and Quality of Patient Care Through the Implementation of a Flow Cytometry Quality Assurance Program.
Dylan Wang, Hong Fang, Chi Young Ok, Jeffrey L Jorgensen, L Jeffrey Medeiros
Archives of Pathology & Laboratory Medicine. 2025-02-01
Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee
Leukemia & Lymphoma. 2025-01-21
Diffuse Large B-Cell Lymphoma/High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements: a study of 60 Cases.
Do Hwan Kim, L Jeffrey Medeiros, Jie Xu, Guilin Tang, Lianqun Qiu
Modern Pathology. 2025-01-11

Journal Articles

High-Grade B-cell Lymphomas with TdT Expression: A Diagnostic and Classification Dilemma
Chi Young Ok, L Jeffrey Medeiros, Sergej Konoplev, Nitin Jain, Elias Jabbour, Guilin Tang, Nature

Abstracts/Posters

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical, Immunophenotypic and Genomic Findings Â of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018